Gabapentin Dementia Lawsuit in Arizona - Free Case Review

Free Case Review

Start Your Free Review

Answer 2-3 quick questions to review your potential case.

Key Takeaway

Arizona's rapidly growing and aging population, combined with a significant chronic pain burden driven by its large retirement and veteran communities, has made gabapentin one of the most prescribed medications in the state. Maricopa County (Phoenix metro) alone accounts for over 60 percent of state prescriptions. Arizona has not scheduled gabapentin as a controlled substance, meaning the drug remains freely prescribable without PDMP reporting requirements — a regulatory gap that may have contributed to overprescribing. The state's large retirement communities in the Sun Belt corridor (Scottsdale, Sun City, Green Valley) concentrate elderly gabapentin patients whose cognitive decline is frequently misattributed to normal aging. Arizona courts have a growing pharmaceutical litigation docket, and the state's product liability framework provides strong plaintiff protections.

Written By

People's Justice Legal Research Team

Statute of Limitations

Arizona: 2 years for personal injury (Ariz. Rev. Stat. § 12-542). Discovery rule applies — limitations begin when the plaintiff discovers or should have discovered the injury and its cause. Arizona also has a 12-year statute of repose for product liability (§ 12-551).

2 years from discovery of injury

Filing Venue

Where to File in Arizona

Arizona gabapentin cases may be filed in the District of Arizona (Phoenix or Tucson divisions) or in Maricopa County Superior Court. Maricopa County has a complex litigation division that handles pharmaceutical cases. Arizona follows pure comparative fault (Ariz. Rev. Stat. § 12-2505), meaning plaintiff recovery is reduced but not barred by contributory negligence. The state does not cap compensatory damages in product liability cases.

Arizona Data

Exposure in Arizona

Source: IQVIA / AZ Board of Pharmacy data

Source: Arizona Board of Pharmacy

Source: U.S. Census Bureau / ACS data

FAQ

Frequently Asked Questions

See details below.

Back to Gabapentin Dementia Lawsuit Lawsuit Overview